OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Computing brain metastasis impact	1718
Digging for treasures in the tumour interactome	1239
An inhospitable site	643
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	595
Fructose takes a detour to feed cancer	594
Implementing practice-changing progress for managing cancer of unknown primary	402
Oncofetal reprogramming in tumour development and progression	398
INVADEseq to study the intratumoural microbiota at host single-cell resolution	388
Combinatorial strategies to target RAS-driven cancers	384
Exploiting metabolic cell death for cancer therapy	371
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	342
Emerging strategies to investigate the biology of early cancer	341
How medical anthropology can contribute to cancer research	335
Mapping the prostate cell family tree	328
Fighting cancer with fat	305
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	294
3D chromatin architecture as a predictor of somatic mutations in cancer genomes	272
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	257
Connie J. Eaves (1944–2024)	247
Antihistamines boost immunotherapy	230
The recruitment of metastasis-associated monocytes	224
The evolution of cancer and ageing: a history of constraint	221
Tertiary lymphoid structures as hubs of antitumour immunity	221
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	214
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	213

Translating premalignant biology to accelerate non-small-cell lung cancer interception	211
Epithelial and stromal co-evolution and complicity in pancreatic cancer	210
Context-dependent functions of pattern recognition receptors in cancer	209
Nanoreceptors take down mutant p53	193
No mutation, tumour initiation	193
Gut microbes produce novel genotoxic metabolites	193
Impersonating neurons	192
Dendritic cells rise and shine	184
Tumour EVPs disrupt liver function	178
AACR 2025	169
Measuring HLA disruption using MHC Hammer	167
Persistence is key	166
Thelpers? More like Ttroublemakers	161
Removing barriers to address sex differences in anticancer drug toxicity	161
Defining a ‘cells to society’ research framework for appendiceal tumours	158
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	151
Remodelling of the tumour microenvironment by the kallikrein-related peptidases	148
3D bioprinted cancer models: from basic biology to drug development	140
Natural killer cells in antitumour adoptive cell immunotherapy	139
Bone voyage: immune crosstalk sets sail	135
How chemokines organize the tumour microenvironment	135
B-ring sterols to the rescue	129
In-depth organoid profiling of pancreatic cancer	127
Visualizing intratumoural heterogeneity with EpicMIBI	126
Un-Fair Skin: racial disparities in acral melanoma research	123
The immune microenvironment of colorectal cancer	123
Identifying spatial cellular structures with SPACE-GM	122
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	121
Points of entry for tumour-infiltrating lymphocytes	121
Regulatory T cells in the tumour microenvironment	118
Leveraging the replication stress response to optimize cancer therapy	117
Linking cell mechanical memory and cancer metastasis	115
The path to leptomeningeal metastasis	113
Dynamics and specificities of T cells in cancer immunotherapy	110
In situ decellularization of tissues to resolve the tumour-associated matrix	104
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	104
Encoding spatial tumour dynamics with Starfysh	101
Understanding and addressing race disparities in childhood cancer outcomes	101
Race influences the tumour microbiome	99
Deciphering the cancer genome and epigenome	95
The link between vitamin D and prostate cancer	92
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic	89
Polygenic scores in cancer	86
ER stress sparks nerve pain	85
Acetyl-CoA metabolism in cancer	84
Cancer nanomedicine	83
Targeted protein degradation for cancer therapy	82
RNA splicing dysregulation and the hallmarks of cancer	79
Z-nucleic acids give immunotherapy a boost	77
Local CAR manufacturing	76

Parity modulates epithelial–immune cell communication	74
Author Correction: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology	73
Prime editing GEMMs to model cancer mutations	71
NOTUM-mediated stem cell competition in CRC	69
Tamoxifen takes the wheel	65
A trojan horse to target spliceosome mutant cells	65
Right ON target: a new RAS-GTP inhibitor	65
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	63
Chromothripsis in cancer	61
Expanding the utility of precision oncology knowledge bases	55
Integrative medicine in oncology: redefining the standard of care	52
Targeting ferroptosis as a vulnerability in cancer	52
Tertiary lymphoid structures in anticancer immunity	51
Neutrophils: a roadblock for immunotherapy	48
Defining precancer: a grand challenge for the cancer community	48
Judith Campisi (1948–2024)	47
Revealing genomic secrets of archival FFPE samples	47
Quantum probes in cancer research	47
In vivo labelling system to study cell neighbourhoods	47
Functional lineage tracing to study the clonal evolution of therapy resistance	46
New pathogen on the block	45
Melanomagenesis antagonizes stem cell ageing	42
Inferring cancer metabolism from gene-expression data	42
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	41
Recent advances in therapeutic cancer vaccines	41
The present and future of the Cancer Dependency Map	40
Carcinogenesis at single-cell resolution	38
Patient-derived organoids unveil sarcoma vulnerabilities	37
Global post-mortem tissue donation programmes to accelerate cancer research	36
Bidirectional CART.BiTE cells bring new hope	36
Transfer RNAs as dynamic and critical regulators of cancer progression	35
Focusing on the complex and dynamic interplay between ageing and cancer	35
Epigenomic heterogeneity as a source of tumour evolution	34
Developing dietary interventions as therapy for cancer	33
A timeline of tumour-associated macrophage biology	33
Traject3d for studying 3D cellular heterogeneity	31
Harnessing the influenza virus to fight cancer	30
Digitally enhanced Raman spectroscopy	30
Author Correction: Integrative medicine in oncology: redefining the standard of care	30
Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer	29
Neuro-immune cross-talk in cancer	26
We cannot ignore the cancer risks of wildfires	26